Akkermansia muciniphila: Uses, Benefits, Dosage & Safety

Last updated: August 2026 · Reviewed by the FactoWiki Editorial Team for clarity and source accuracy

What is Akkermansia muciniphila?

Akkermansia muciniphila lives in the mucus layer of the gut and makes up 1–4% of the gut microbiota in healthy adults. It is consistently depleted in people with obesity, type 2 diabetes and inflammatory bowel disease. It is called a next-generation probiotic because it is not one of the traditional Lactobacillus or Bifidobacterium species.

What Akkermansia muciniphila is commonly used for

Metabolic health, insulin sensitivity, gut barrier integrity and weight management support.

How Akkermansia muciniphila works

Akkermansia feeds on the intestinal mucus layer and, paradoxically, stimulates the host to produce more of it — strengthening rather than eroding the gut barrier. A specific outer membrane protein, Amuc_1100, appears to drive much of the effect through TLR2 signalling. Because that protein survives pasteurisation, the heat-killed bacterium retains activity, which is why pasteurised preparations outperformed live ones in trial.

What the evidence says

Each claim below is tied to the specific study behind it, rather than to a general reading list.

• Three months of pasteurised A. muciniphila improved insulin sensitivity by ~29%, reduced insulinaemia and lowered total cholesterol versus placebo in overweight insulin-resistant adults. Depommier et al., Nature Medicine, 2019 — randomised, double-blind, placebo-controlled trial (n=40). (PMID 31263284)
• Pasteurised A. muciniphila reduced weight regain after a low-energy diet (1.2 kg vs 3.2 kg on placebo) over 24 weeks. Nature Medicine, 2026 — randomised controlled trial (n=90), ClinicalTrials.gov NCT05417360. (PMID 42120725)
• The Amuc_1100 membrane protein reproduces the metabolic effect and survives pasteurisation. Plovier et al., Nature Medicine, 2017 — mechanistic and preclinical study. (PubMed)

Typical dosage used in studies

10¹⁰ bacteria (10 billion) per day is the dose used in the published human trials, of the pasteurised form. Effects on metabolic markers emerged over three months.

Side effects and safety

In the human trials, daily supplementation for three months was safe and well tolerated, with no serious treatment-related adverse events. Mild digestive symptoms occurred in some participants.

Medication interactions and who should avoid Akkermansia muciniphila

Sources & further reading

The claim-level citations above are drawn from these sources:

• Depommier et al., Nature Medicine, 2019 — randomised, double-blind, placebo-controlled trial (n=40) — PMID 31263284
• Nature Medicine, 2026 — randomised controlled trial (n=90), ClinicalTrials.gov NCT05417360 — PMID 42120725
• Plovier et al., Nature Medicine, 2017 — mechanistic and preclinical study — find on PubMed
• NIH Office of Dietary Supplements
• NIH National Center for Complementary and Integrative Health

Frequently asked questions

Why is the dead version better than the live one?

Because the active component is a heat-stable outer membrane protein, and pasteurisation appears to improve its availability. This is genuinely unusual — for most probiotics, viability is the point.

Does Akkermansia cause weight loss?

Not on its own. The 2026 trial showed reduced weight regain after dieting, not weight loss without one. That is a narrower and more honest claim than most marketing makes.

Can I raise my own Akkermansia levels with diet?

Partly. Polyphenol-rich foods, fibre and cranberry or pomegranate extracts are associated with higher levels. Whether that matches supplementation is unknown.

General information, not medical advice.